Skip to Content

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

After over six years of follow-up, pembrolizumab added to chemotherapy significantly improves event-free and overall survival in triple-negative breast cancer. The KEYNOTE-522 trial, presented by Peter Schmid at ESMO 2024 as a late breaking abstract (LBA4).

Peter Schmid

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top